Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Respiration. 2013;86(6):472-8. doi: 10.1159/000348374. Epub 2013 May 8.
Few studies have investigated the impact of diabetes mellitus (DM), a globally increasing metabolic disease, on treatment outcomes and long-term survival in patients with multidrug-resistant forms of tuberculosis (MDR-TB).
We analyzed outcomes in a large cohort to assess the impact of DM on treatment outcomes of patients with MDR-TB.
MDR-TB patients newly diagnosed or retreated between 2000 and 2002 and followed for 8-11 years were retrospectively analyzed with respect to the effect of DM as a comorbidity on their treatment outcome and long-term survival.
Of 1,407 patients with MDR-TB, 239 (17.0%) had coexisting DM. The mean age and body mass index were higher in MDR-TB patients with DM [MDR-TBDM(+)] than in those without DM [MDR-TBDM(-)]. Patients with MDR-TB and a comorbidity of DM had a significantly lower treatment success rate than those without a history of DM (36.0 vs. 47.2%, p = 0.002). In addition, DM was the negative predictor for MDR-TB treatment success in multivariate analyses [odds ratio 0.51, 95% confidence interval (CI) 0.26-0.99]. Mean survival times were also lower in MDR-TBDM(+) than in MDR-TBDM(-) patients (102 vs. 114 months, p = 0.001), with DM as a significant predictor of poor long-term survival in multivariate analyses (hazard ratio 1.59, 95% CI 1.01-2.50).
Among MDR-TB patients, DM was a relatively common comorbidity. In patients undergoing treatment for MDR-TB and followed for 8-11 years, it was found to be independently associated with an increased risk of both treatment failure and death.
糖尿病(DM)是一种在全球范围内不断增加的代谢性疾病,鲜有研究调查其对耐多药结核病(MDR-TB)患者的治疗结局和长期生存的影响。
我们分析了一个大型队列的结果,以评估 DM 对 MDR-TB 患者治疗结局的影响。
对 2000 年至 2002 年间新诊断或复治的 MDR-TB 患者进行回顾性分析,研究 DM 作为合并症对其治疗结局和长期生存的影响。
在 1407 例 MDR-TB 患者中,239 例(17.0%)合并 DM。合并 DM 的 MDR-TB 患者的平均年龄和体重指数(BMI)均高于无 DM 的患者(MDR-TBDM(-))。与无 DM 病史的患者相比,合并 DM 的 MDR-TB 患者的治疗成功率显著较低(36.0% vs. 47.2%,p=0.002)。此外,在多变量分析中,DM 是 MDR-TB 治疗成功的负预测因子(比值比 0.51,95%置信区间[CI] 0.26-0.99)。MDR-TBDM(+)患者的平均生存时间也短于 MDR-TBDM(-)患者(102 个月 vs. 114 个月,p=0.001),DM 是多变量分析中不良长期生存的显著预测因子(风险比 1.59,95%CI 1.01-2.50)。
在 MDR-TB 患者中,DM 是一种常见的合并症。在接受 MDR-TB 治疗并随访 8-11 年的患者中,发现 DM 与治疗失败和死亡风险增加独立相关。